– Femasys demonstrates compliance with harmonized regulatory requirements for Australia, Brazil, Japan, Canada and the USA – – Femasys is committed…
NME is a progressive, typically fatal autoimmune disease characterized by brain inflammation, that has no disease-modifying treatment options availableSAN DIEGO…
Company to Host Cancer R&D Update on October 19, 2023 to Share Latest Details of Multipronged Cancer Program Based on…
Toronto, Ontario--(Newsfile Corp. - October 3, 2023) - Neural Therapeutics Inc. ("Neural" or the "Company") is pleased to announce the…
9th Circuit Court of Appeals Orders DEA to Respond to MMJ's Writ of Mandamus Within 30 DaysWASHINGTON D.C. / ACCESSWIRE…
PARSORTIX SYSTEM OUTPERFORMS CURRENT LABORATORY STANDARD FOR DISSEMINATED TUMOUR CELL HARVEST DTCs linked to cancer relapse even after prolonged remissionDTCs…
Provides framework for improving quality and equity of digital technology-enabled care modelsWASHINGTON, DC / ACCESSWIRE / October 2, 2023 /…
Based on pioneering research from Mayo Clinic, ECG-AI LEF aims to aid physicians in identifying low ejection fraction in patients…
804 Alzheimer’s Patients Are Enrolled in a Pivotal Phase 3 Clinical TrialA Second Pivotal Phase 3 Clinical Trial Is Expected…
- Bipartisan resolution highlights the challenges patients with rare cancers face and raises awareness and supports efforts to improve early…